Canada: December 2016 Deal Round-Up

Last Updated: January 10 2017
Article by Cameron Mingay

The following is a summary of major deals in the life science space that closed or were announced in December 2016.

December 2016 continued to see activity among cannabis stocks, but one of the most notable transactions was the launch of BlueRock Therapeutics by Bayer AG and Versant Ventures, Inc. with a combined Series A funding round of US $225 million.

Date: Announced December 1, 2016

Acquirer: Canopy Growth Corporation (TSX: CGC)

Target: Mettrum Health Corp. (TSXV: MT)

Deal size: Approx. CDN $430 million

Description: On December 1, 2016 Canopy Growth Corporation ("Canopy Growth") and Mettrum Health Corp. ("Mettrum") announced that they entered into a definitive arrangement agreement (the "Arrangement Agreement") under which Canopy Growth will acquire all of the issued and outstanding shares of Mettrum. The total transaction is valued at approximately CDN $430 million and will be satisfied by the issuance of common shares in Canopy Growth. Under the terms of the Arrangement Agreement, Mettrum shareholders will be entitled to receive 0.7132 common shares of Canopy Growth for each common share of Mettrum, representing consideration of CDN $8.42 per Mettrum common share based on the closing price of Canopy Growth common shares on the Toronto Stock Exchange on November 30, 2016.

Source: Press Release, "Canopy Growth Enters into Agreement to Acquire Mettrum", December 1, 2016.
Date: December 9, 2016

Type: Bought deal private placement offering

Issuer: Immunovaccine Inc. (TSX: IMV)

Underwriter(s): A syndicate of underwriters led by Echelon Wealth Partners Inc., and including Mackie Research Capital corporation.

Deal size: Approx. $8 million

Description: On December 9, 2016, Immunovaccine Inc. ("Immunovaccine") announced that it had closed a bought deal private placement offering (the "Offering"), raising gross proceeds of $8,000,000.25. Under the terms of the Offering, a total of 10,666,667 common shares (the "Common Shares") were issued at a price of $0.75 per Common Share (the "Issue Price"). The Offering was completed through a syndicate of underwriters led by Echelon Wealth Partners Inc. and including Mackie Research Capital Corporation. As part of the Offering, the Company granted to the Underwriters an over-allotment option, which entitles the Underwriters to purchase, during the period ending January 9, 2017, up to an additional 1,600,000 Common Shares at the Issue Price, for additional gross proceeds of up to $1,200,000. Immunovaccine is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and infectious disease vaccines.

Source: Press Release, "Immunovaccine Announces Closing of $8 Million Bought Deal Private Placement Financing", December 9, 2016.
Date: Announced December 12, 2016

Type: Series A financing

Issuer: BlueRock Therapeutics

Investor(s): Bayer AG and Versant Ventures, Inc.

Deal size: US $225 million

Description: On December 12, 2016, Bayer AG and Versant Ventures announced the launch of BlueRock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies for a range of diseases. BlueRock Therapeutics was launched with a US $225 million Series A funding round, representing one of the largest ever Series A financings for a biotechnology company.

Source: Press Release, "Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing", December 12, 2016.
Date: December 13, 2016

Type: Bought deal private placement (the "Brokered Offering") and concurrent non-brokered private placement (together with the Brokered Offering, the "Offering")

Issuer: Supreme Pharmaceuticals Inc. (CSE: SL)

Underwriter(s): The syndicate for the Brokered Offering was led by Canaccord Genuity Corp. and included Dundee Securities Ltd., Beacon Securities Limited and Cormark Securities Inc.

Deal size: $55 million ($50 million bought deal private placement and $5 million non-brokered private placement)

Description: On December 13, 2016, Supreme Pharmaceuticals Inc. ("Supreme") announced the closing of a $50 million bought deal private placement (the "Brokered Offering") and concurrent $5 million non-brokered private placement (together with the Brokered Offering, the "Offering") for aggregate gross proceeds of $55 million. Under the Offering, Supreme issued a total of $55 million of 10% unsecured convertible debentures (the "Debentures") and 42,350,000 common share purchase warrants ("Warrants").

The Debentures bear interest from the date of closing at 10.0% per annum, payable semi-annually on June 30 and December 31 of each year and will mature on December 31, 2019. The Debentures are convertible at the option of the holder into common shares in the capital of Supreme ("Common Shares") at any time prior to the close of business on December 31, 2019 at a conversion price of $1.30 per Common Share (the "Conversion Price"), subject to Supreme's ability to force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price in certain circumstances. Each Warrant is exercisable to acquire one Common Share of the Corporation at an exercise price of $1.70 per Common Share for a period of three years following December 13, 2016, subject to Supreme's right to accelerate expiry at any time after four months and one day after December 13, 2016 in certain circumstances.

Source: Supreme Pharmaceuticals Inc., Form 51-102F3 Material Change Report, December 22, 2016.
Date: December 13, 2016

Type: Private placement and asset purchase

Issuer: Neovasc Inc. (TSX: NVC) (NASDAQ: NVCN)

Investor(s)/Acquiror(s): Boston Scientific Corporation (NYSE: BSX)

Deal size: US $7,090,200 (private placement) and US $67,909,800 (asset purchase)

Description: On December 12, 2016, Neovasc Inc. ("Neovasc") completed its transaction with Boston Scientific Corporation ("Boston Scientific") whereby Boston Scientific acquired Neovasc's advanced biologic tissue capabilities and certain manufacturing assets for US$67,909,800. Concurrently, Neovasc completed a private placement whereby Boston Scientific purchased 11,817,000 common shares in the capital of Neovasc (the "Common Shares") at a purchase price of US$0.60 per Common Share for gross proceeds of US$7,090,200. Neovasc is a specialty medical device company that develops, manufactures and markets certain products to address cardiovascular diseases such as mitral valve disease and refractory angina.

Source: Press Release, "Neovasc and Boston Scientific Close US $75 Million Agreement", December 13, 2016
Date: December 22, 2016

Type: Bought deal offering

Issuer: Canopy Growth Corporation (TSX: CGC)

Underwriter(s): A syndicate of underwriters led by GMP Securities L.P. and Dundee Capital Partners, and including Cormark Securities Inc., PI Financial Corp., and Canaccord Genuity Corp.

Deal size: $60,017,200

Description: On December 22, 2016, Canopy Growth Corporation ("Canopy Growth") announced that it had closed its previously announced short form prospectus offering on a bought deal basis. A total of 5,662,000 common shares in the capital of the company (the "Common Shares") were sold at a price of $10.60 per Common Share for aggregate gross proceeds of $60,017,000.

Source: Press Release, "Canopy Growth Corproation completes previously announced bought deal financing for $60 million", December 22, 2016

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.